You have 9 free searches left this month | to do more

empagliflozin

Empagliflozin is a drug used to treat Diabetes Mellitus, Type 2, Healthy, Heart Failure, and other conditions. Empagliflozin is being actively studied in 37 studies and prior, has been studied in 61.

Top SponsorsTop SitesTop Investigators
Boehringer IngelheimCharite - Universitatsmedizin BerlinAnton Borisov
EMSEast Coast Institute for Research, LLCCHEOL WHAN LEE, M.D., Ph.D
Getz PharmaThe University of North Carolina at Chapel HillCaroline M Kistorp
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
H
Pharmacokinetic Drug Interaction Between Teneligliptin and Empagliflozin - 2021
Completed
  • Type 2 Diabetes Mellitus
  • Seoul, Korea, Republic of
    Clinical Pharmacology, Asan Medical Center
2021-11-08
Nov 8, 2021
S
Effect of Empagliflozin and Dulaglutide on MAFLD in Patients With T2D
Not yet recruiting
  • Metabolic-associated Fatty Liver Disease
  • Type 2 Diabetes
  • Empagliflozin
  • +2 more
  • (no location specified)
2021-12-15
Dec 15, 2021
O
Empagliflozin in Adolescent Diabetes
Not yet recruiting
  • type1diabetes
  • Empagliflozin
  • Columbus, Ohio
    Ohio State University
2021-06-07
Jun 7, 2021
U
Empagliflozin and Anakinra for the Treatment of Postprandial Hypoglycemia in Patients With Prediabetes
Not yet recruiting
  • Postprandial Hypoglycemia
  • empagliflozin
  • +3 more
  • Basel, Switzerland
    Department of Endocrinology, Diabetes and Metabolism, University
2022-01-19
Jan 19, 2022
B
Comparative Effectiveness of Empagliflozin in the US
Active, not recruiting
  • Diabetes Mellitus, Type 2
  • Empagliflozin
  • +2 more
  • Boston, Massachusetts
    Bringham Women Hospital
2022-04-04
Apr 4, 2022
H
Prospective Cohort Study of Children With GSD1b Receiving Empagliflozin
Recruiting
  • Glycogen Storage Disease Type IB
  • Empagliflozin
  • Hong Kong, Hong Kong
    Hong Kong Children's Hospital
2021-08-08
Aug 8, 2021
M
Empagliflozin and Atrial Fibrillation Treatment
Not yet recruiting
  • Atrial Fibrillation
  • +3 more
  • Empagliflozin
  • Placebo
  • Acquaviva Delle Fonti, Bari, Italy
    Miulli General Hospital
2021-04-01
Apr 1, 2021
B
A Study Based on Data From German Sick Funds That Looks at the Costs of Treatment of Type-2 Diabetic Patients With Empagliflozin vs. DPP-4 Inhibitors vs. GLP-1 Receptor Agonists - 2021
Completed
  • Diabetes Mellitus, Type 2
  • Empagliflozin
  • +3 more
  • Ingelheim am Rhein, Germany
    Boehringer Ingelheim
2022-01-18
Jan 18, 2022
C
Head-to-head Comparison of Empagliflozin and Dapagliflozin
Active, not recruiting
  • Type2 Diabetes
  • Cheonju, Chungcheongbuk-do, Korea, Republic of
    Chungbuk National University Hospital
2021-11-02
Nov 2, 2021
U
Effects of Empagliflozin on Endogenous Glucose Production in End Stage Renal Disease(ESRD). - 2020
Completed
  • End Stage Renal Disease
  • Empagliflozin
  • Placebo
  • Pisa, Italy
    Department of Endocrinology and Metabolism, University of Pisa
2021-09-13
Sep 13, 2021
B
This Study Combines Data From 3 Other Studies Testing Empagliflozin in Patients With Diabetes or With Chronic Heart Failure. The Study Looks at the Numbers of Patients Who Had Lower Limb Amputations - 2021
Completed
  • Diabetes Mellitus, Type 2
  • Placebo
  • Empagliflozin
  • Ingelheim am Rhein, Germany
    Boehringer Ingelheim
2022-01-18
Jan 18, 2022
C
Safety and Efficacy of Empagliflozin in GSD1b Patients With Neutropenia
Not yet recruiting
  • Glucose 6 Phosphatase Deficiency
  • Empagliflozin
  • Warsaw, Poland
    The Children's Memorial Health Institute
2021-06-18
Jun 18, 2021
N
Empagliflozin as a Treatment for Severe Congenital Neutropenia Due to G6PC3 Deficiency
Recruiting
  • Crohn's Disease
  • +2 more
  • Empagliflozin
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
2022-04-07
Apr 7, 2022
B
A Study Using Swedish Registries to Find Out How Many People With Type 2 Diabetes Had Cardiovascular Disease and Started Treatment With Empagliflozin Between 2015 and 2017 - 2018
Completed
Has Results
  • Type 2 Diabetes Mellitus
  • Empagliflozin
  • Stockholm, Sweden
    Boehringer Ingelheim AB
2021-07-21
Jul 21, 2021
N
Effects of Empagliflozin on Exercise Capacity and Left Ventricular Diastolic Function in Patients With Heart Failure With Preserved Ejection Fraction and Type-2 Diabetes Mellitus - 2022
Completed
  • Heart Failure, Diastolic
  • Diabetes Mellitus, Type 2
  • Empagliflozin
  • Standard care
  • Moscow, Russian Federation
    National Medical Research Center for Cardiology
2022-01-10
Jan 10, 2022
B
A Study Using Medical Records of Danish People With Type 2 Diabetes Comparing Empagliflozin and Glucagon-Like Peptide-1 Receptor Agonists (GLP1-RA) in the Occurrence of Serious Cardiovascular Outcomes
Active, not recruiting
  • Diabetes Mellitus, Type 2
  • Empagliflozin
  • Glucagon-Like Peptide-1 Receptor Agonists (GLP1-RA)
  • Aarhus, Denmark
    Department of Clinical Epidemiology - Aarhus Unversiteteshospita
2022-03-07
Mar 7, 2022
G
Real World Safety & Efficacy Experience of Empagliflozin With or Without Metformin in T2DM Patients - EASE Study
Active, not recruiting
  • Type II Diabetes Mellitus
  • +2 more
  • Empagliflozin
  • Islamabad, Pakistan
    Umar Diabetes Foundation
2021-12-20
Dec 20, 2021
B
To Assess the Risk of Acute Pancreatitis in Patients With Type 2 Diabetes Mellitus Treated With Empagliflozin
Active, not recruiting
  • Diabetes Mellitus, Type 2
  • empagliflozin
  • Oral non-incretin/non-sodium glucose co-transporter-2 inhibitors (SGLT2)-containing hypoglycaemic agents
  • Ingelheim am Rhein, Germany
    Boehringer Ingelheim International GmbH
2022-04-05
Apr 5, 2022
U
Empagliflozin and Cardiac Remodelling in People Without Diabetes
Recruiting
  • Cardiovascular Diseases
  • Left Ventricular Hypertrophy
  • Empagliflozin
  • Placebo
  • Toronto, Ontario, Canada
  • +3 more
2021-06-14
Jun 14, 2021
B
Clinical Outcomes and Healthcare Cost and Resource Utilization (HCRU) in Patients With Type 2 Diabetes and Cardiovascular Disease on 2nd Line Empagliflozin Versus 2nd Line Sulfonylureas
Active, not recruiting
  • Diabetes Mellitus, Type 2
  • Cardiovascular Diseases
  • empagliflozin
  • +2 more
  • Ridgefield, Connecticut
    Boehringer Ingelheim Pharmaceuticals Inc
2022-03-07
Mar 7, 2022
H
The Effect Effect of Empagliflozin on Oxidative Stress in Patients With Type 2 Diabetes - 2020
Completed
  • Diabetes Mellitus, Type 2
  • Empagliflozin
  • Placebo
  • Hellerup, Denmark
    Center for Diabetes Research, Gentofte Hospital
2021-06-09
Jun 9, 2021
B
A Study to Learn How Well the Treatment Combination of Finerenone and Empagliflozin Works and How Safe it is Compared to Each Treatment Alone in Adult Participants With Long-term Kidney Disease (Chronic Kidney Disease) and Type 2 Diabetes
Not yet recruiting
  • Type 2 Diabetes Mellitus
  • Chronic Kidney Disease
  • Finerenone (Kerendia, BAY94-8862 )
  • +2 more
  • Savannah, Georgia
  • +12 more
2022-04-07
Apr 7, 2022
B
A Study to Test Whether BI 685509 Alone or in Combination With Empagliflozin Helps People With Liver Cirrhosis Caused by Viral Hepatitis or Non-alcoholic Steatohepatitis (NASH) Who Have High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver)
Not yet recruiting
  • Liver Diseases
  • Hypertension, Portal
  • BI 685509
  • Empagliflozin
  • (no location specified)
2022-04-04
Apr 4, 2022
I
Are the "Cardiac Benefits" of Empagliflozin Independent of Its Hypoglycemic Activity? (ATRU-4). - 2020
Completed
Has Results
  • Cardiovascular Diseases
  • Empagliflozin
  • Placebos
  • New York, New York
    Mount Sinai Heart - Icahn School of Medicine at Mount Sinai
2021-03-02
Mar 2, 2021
M
Study to Evaluate MET409 Alone or in Combination With Empagliflozin in Patients With Type 2 Diabetes and NASH
Active, not recruiting
  • NASH
  • +7 more
  • MET409 Active
  • +2 more
  • Fort Myers, Florida
  • +1 more
2021-05-28
May 28, 2021